Literature DB >> 10192668

Comparison of topical anesthetics and vasoconstrictors vs lubricants prior to nasogastric intubation: a randomized, controlled trial.

A J Singer1, N Konia.   

Abstract

OBJECTIVE: To determine whether pre-treatment of the nose and throat with topical anesthetics and vasoconstrictors would reduce the pain associated with nasogastric (NG) intubation.
METHODS: This was a prospective, randomized, controlled trial assessing the pain of NG intubation in patients pretreated with topical anesthetics and vasoconstrictors vs surgical lubricants alone. The subjects were 40 alert, cooperative adult patients requiring NG intubation without allergies to the study medications or contraindications to their use from a suburban university-based ED. The patients in the experimental group had phenylephrine 0.5% sprayed in their noses followed by instillation of 5 mL of 2% lidocaine jelly. Their throats were sprayed with 2% tetracaine and 14% benzocaine. The control patients received intranasal lubrication only. The primary outcome measured was pain of NG intubation on a 100-mm visual analog scale. Other outcomes included nasal pain, discomfort from gagging, and the incidences of vomiting, choking, and epistaxis.
RESULTS: The mean age (+/-SD) was 54.8+/-22.3 years; 20 (50%) were female. The patients who had a combination of topical anesthetics and vasoconstrictors inserted prior to NG intubation experienced significantly less overall pain/ discomfort than did the control patients [28.6 mm (95% CI = 17.3 to 39.9 mm) vs 57.5 mm (95% CI = 44.9 to 70.1 mm), p = 0.001]. The patients in the experimental group also experienced significantly less nasal pain than did the patients in the control group [18.1 mm (95% CI = 8.0 to 28.2 mm) vs 44.4 mm (95% CI = 30.4 to 58.6 mm), p = 0.003] and significantly less discomfort from gagging than the patients receiving pretreatment with a lubricant alone [24.1 mm (95% CI = 11.1 to 37.1 mm) vs 50.9 mm (95% CI = 36.7 to 65.1 mm), p = 0.006]. There was no between-group difference in the frequencies of adverse effects.
CONCLUSIONS: Use of topical lidocaine and phenylephrine for the nose and tetracaine with benzocaine spray for the throat prior to NG intubation results in significantly less pain and discomfort than use of a nasal surgical lubricant alone. Widespread use of topical anesthetics and vasoconstrictors prior to NG intubation is recommended.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10192668     DOI: 10.1111/j.1553-2712.1999.tb00153.x

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN: 1069-6563            Impact factor:   3.451


  5 in total

1.  Cervical lidocaine for IUD insertional pain: a randomized controlled trial.

Authors:  Colleen P McNicholas; Tessa Madden; Qiuhong Zhao; Gina Secura; Jenifer E Allsworth; Jeffrey F Peipert
Journal:  Am J Obstet Gynecol       Date:  2012-09-20       Impact factor: 8.661

2.  Lignocaine/phenylephrine nasal spray vs. placebo for the pain and distress of nasogastric tube insertion in children: a study protocol for a randomized controlled trial.

Authors:  Simon S Craig; Robert W Seith; John A Cheek; Adam West; Kathryn Wilson; Diana Egerton-Warburton
Journal:  Trials       Date:  2015-01-27       Impact factor: 2.279

3.  A Safety Evaluation of Midazolam use for Nasogastric Tube Placement.

Authors:  Jenna B Wells; David H Murman; Alison L Sullivan
Journal:  J Res Pharm Pract       Date:  2021-12-25

Review 4.  Management of procedural pain in the intensive care unit.

Authors:  Na-Na Guo; Hong-Liang Wang; Ming-Yan Zhao; Jian-Guo Li; Hai-Tao Liu; Ting-Xin Zhang; Xin-Yu Zhang; Yi-Jun Chu; Kai-Jiang Yu; Chang-Song Wang
Journal:  World J Clin Cases       Date:  2022-02-16       Impact factor: 1.337

Review 5.  The application of lidocaine to alleviate the discomfort of nasogastric tube insertion: A systematic review and meta-analysis.

Authors:  You-Chen Lor; Pei-Ching Shih; Hsin-Hao Chen; Shu-Jung Liu; Hsingchu-Chu Chao; Lee-Ching Hwang; Yen-Fen Hsu; Tzu-Lin Yeh
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.